Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide GnRH Antagonist Elagolix
OA: closed
CC0
AI-generated summary
This study evaluated the safety, pharmacokinetics, and inhibitory effects of the oral nonpeptide GnRH antagonist elagolix on gonadotropins and estradiol in healthy premenopausal women.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ABSTRACT Context: Parenteral administration of peptide GnRH analogs is widely employed for treatment of endometriosis, fibroids and in assisted-reproductive therapy protocols. Elagolix is a novel, orally available nonpeptide GnRH antagonist. Objective: To evaluate the safety, pharmacokinetics and inhibitory effects on gonadotropins and estradiol of single dose and 7-day elagolix administration to healthy premenopausal women. Design: This was a first-in-human, double-blind, placebo-controlled, single- and multiple dose study with sequential dose-escalation. Participants: Fifty-five healthy, regularly cycling pre-menopausal women. Interventions: Subjects were administered a single oral dose of 25 to 400 mg or placebo. In a second arm of the study, subjects received placebo or 50, 100, or 200 mg q.d. or 100 mg b.i.d. for seven days. Treatment was initiated on Day 7 (±1) following onset of menses. Main Outcome Measures: Safety, tolerability, pharmacokinetics and serum LH, FSH and estradiol concentrations.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (23)
- Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray via openalex
- Gonadotropin-releasing hormone and its analogues via openalex
- Hormone treatment of endometriosis: the estrogen threshold hypothesis via openalex
- Induction of hot flashes in premenopausal women treated with a long-acting GnRH agonist via openalex
- Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy) via openalex
- Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain via openalex
- W2077563872 via openalex
- W2086184133 via openalex
- W2096464233 via openalex
- W2096468320 via openalex
- W2125724273 via openalex
- W2133484074 via openalex
- W2149714875 via openalex
- W2405710866 via openalex
- W2408619637 via openalex
- W2413820230 via openalex
- W133578770 via openalex
- W3104447906 via openalex
- W1976687715 via openalex
- W1981222718 via openalex
- W2034168075 via openalex
- W2060170224 via openalex
- W2075213800 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK